Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 150 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Agenus Inc | AGEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 12.12 | 04:37:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 12.12 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 4 | 150 | - | 4.775 - 42.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:50:38 | 50 | $ 12.00 | USD |
Agenus Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.08B | 418.92M | - | 156.87M | -245.97M | -0.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Agenus News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGEN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.84 | 14.24 | 6.31 | 11.16 | 1,915,283 | 5.28 | 77.19% |
| 1 Month | 10.40 | 14.24 | 4.775 | 9.44 | 5,476,552 | 1.72 | 16.54% |
| 3 Months | 14.374 | 18.98 | 4.775 | 12.58 | 9,219,064 | -2.25 | -15.68% |
| 6 Months | 15.80 | 18.98 | 4.775 | 13.69 | 9,970,681 | -3.68 | -23.29% |
| 1 Year | 30.20 | 42.60 | 4.775 | 18.63 | 7,422,434 | -18.08 | -59.87% |
| 3 Years | 62.00 | 135.80 | 4.775 | 42.40 | 5,515,769 | -49.88 | -80.45% |
| 5 Years | 51.40 | 135.80 | 4.775 | 48.19 | 4,142,651 | -39.28 | -76.42% |
Agenus Description
| Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. |
